A recent post-hoc analysis of the PROSPER trial, published in JHEP Reports (2025), highlights the impact of pravastatin in reducing all-cause mortality in elderly patients at risk of liver fibrosis.
The study examined 5,804 elderly patients (>70 years) at increased cardiovascular risk, using the FIB-4 score to classify liver fibrosis risk. In the placebo group, patients with high FIB-4 scores (≥2.67) had a 54% higher risk of all-cause mortality. However, in the pravastatin-treated group, this excess mortality risk disappeared, suggesting a protective effect of statins in this population.
Notably, high FIB-4 scores were not significantly linked to major adverse cardiovascular events (MACE), emphasizing the unique role of liver fibrosis in overall mortality risk.
These findings support the potential benefits of pravastatin beyond cardiovascular protection, particularly in elderly patients with liver fibrosis risk.
Published in JHEP Reports: https://lnkd.in/eqb7ZJkT
